PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-49.81%
Negative EBIT growth while CRON.TO is at 0.00%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-49.81%
Negative operating income growth while CRON.TO is at 0.00%. Joel Greenblatt would press for urgent turnaround measures.
-52.65%
Negative net income growth while CRON.TO stands at 0.00%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-52.63%
Negative EPS growth while CRON.TO is at 0.00%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-52.63%
Negative diluted EPS growth while CRON.TO is at 0.00%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
-0.38%
Share reduction while CRON.TO is at 0.00%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-0.38%
Reduced diluted shares while CRON.TO is at 0.00%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
71.85%
OCF growth of 71.85% while CRON.TO is zero. Bruce Berkowitz would see if small gains can expand into a larger competitive lead.
71.85%
FCF growth of 71.85% while CRON.TO is zero. Bruce Berkowitz would see if modest improvements in free cash can accelerate further.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.97%
Negative 10Y OCF/share CAGR while CRON.TO stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-100.97%
Negative 5Y OCF/share CAGR while CRON.TO is at 0.00%. Joel Greenblatt would question the firm’s operational model or cost structure.
-100.97%
Negative 3Y OCF/share CAGR while CRON.TO stands at 0.00%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
14.33%
10Y net income/share CAGR of 14.33% while CRON.TO is zero. Bruce Berkowitz would see if minor gains can compound into a bigger lead over time.
14.33%
Net income/share CAGR of 14.33% while CRON.TO is zero. Bruce Berkowitz would see if small mid-term gains can develop into a bigger lead.
14.33%
3Y net income/share CAGR of 14.33% while CRON.TO is zero. Bruce Berkowitz sees if minor improvements can widen to a bigger advantage.
-49.46%
Negative equity/share CAGR over 10 years while CRON.TO stands at 0.00%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-49.46%
Negative 5Y equity/share growth while CRON.TO is at 0.00%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-49.46%
Negative 3Y equity/share growth while CRON.TO is at 0.00%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
68.23%
AR growth of 68.23% while CRON.TO is zero. Bruce Berkowitz wonders if the firm’s additional AR is warranted by strong revenue or potential risk.
No Data
No Data available this quarter, please select a different quarter.
0.03%
Asset growth of 0.03% while CRON.TO is zero. Bruce Berkowitz checks if modest expansions can create a longer-term lead.
-5.52%
We have a declining book value while CRON.TO shows 0.00%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
49.82%
SG&A growth of 49.82% while CRON.TO is zero. Bruce Berkowitz sees more spend on admin or marketing, expecting stronger top-line in return.